story of the week
Ocrelizumab Concentration Is a Good Predictor of SARS-CoV-2 Vaccination Response in Patients With MS
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Annals of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Ocrelizumab concentration is a good predictor of SARS-CoV-2 vaccination response in patients with multiple sclerosis
Ann. Neurol 2022 Oct 17;[EPub Ahead of Print], ZLE van Kempen, L Hogenboom, AA Toorop, M Steenhuis, EW Stalman, LYL Kummer, PJ van Dam, K Bloem, A Ten Brinke, SM van Ham, TW Kuijpers, GJ Wolbink, FC Loeff, L Wieske, F Eftimov, T Rispens, EMM Strijbis, J KillesteinFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.